SEC Comment Letter for Microbot Medical Inc. (MBOT) (CIK 0000883975) (MBOT) — Nov 17, 2010
Microbot Medical Inc. (MBOT) (CIK 0000883975)
Date: Nov. 17, 2010 · CIK: 0000883975 · Accession: 0000000000-10-068699
AI Filing Summary & Sentiment
File numbers found in text: 000-19871
Letter
November 17, 2010
Kenneth B. Stratton General Counsel StemCells, Inc. 3155 Porter Drive Palo Alto, CA 94304 Re: StemCells, Inc. Form 10-K for the Fiscal Year Ended December 31, 2009 Definitive Proxy Statement filed April 13, 2010 File No. 000-19871 Dear Mr. Stratton:
We have reviewed your September 28, 2010 response to our September 15, 2010 letter and have the following comment. Please respond to this letter within te n business days by providing the requested information. If you do not believe our comment a pplies to your facts a nd circumstances, please tell us why in your response. After reviewing the information you provide in response to this comment, we may have additional comments. Definitive Proxy Statement filed April 13, 2010
Executive Compensation, page 11
Bonus Compensation, page 14
1. We note your response to prior comment 5 and reissue our comment. A detailed description of the specific co rporate goals, though subjective and not linearly tied to the compensation committee’s bonus determination, is material to understanding how you incentivize and reward your executive officers. Such detailed description has not been provided by your previous response on July 6, 2010. Please confirm that you will provide a detailed description of the specifi c corporate goals approved by the board for 2010 corporate performance in your 2011 proxy stat ement. To the extent that you goals are quantified, confirm that the description of your goals in your proxy statement will also be quantified.
Kenneth B. Stratton StemCells, Inc. November 17, 2010 Page 2
You may contact Karen Ubell, Staff Attorn ey, at (202) 551-3873, Suzanne Hayes, Legal Branch Chief, at (202) 551-3675 or me at (202) 551-3715 with any questions. Sincerely,
Jeffrey Riedler Assistant Director
Show Raw Text
November 17, 2010 Kenneth B. Stratton General Counsel StemCells, Inc. 3155 Porter Drive Palo Alto, CA 94304 Re: StemCells, Inc. Form 10-K for the Fiscal Year Ended December 31, 2009 Definitive Proxy Statement filed April 13, 2010 File No. 000-19871 Dear Mr. Stratton: We have reviewed your September 28, 2010 response to our September 15, 2010 letter and have the following comment. Please respond to this letter within te n business days by providing the requested information. If you do not believe our comment a pplies to your facts a nd circumstances, please tell us why in your response. After reviewing the information you provide in response to this comment, we may have additional comments. Definitive Proxy Statement filed April 13, 2010 Executive Compensation, page 11 Bonus Compensation, page 14 1. We note your response to prior comment 5 and reissue our comment. A detailed description of the specific co rporate goals, though subjective and not linearly tied to the compensation committee’s bonus determination, is material to understanding how you incentivize and reward your executive officers. Such detailed description has not been provided by your previous response on July 6, 2010. Please confirm that you will provide a detailed description of the specifi c corporate goals approved by the board for 2010 corporate performance in your 2011 proxy stat ement. To the extent that you goals are quantified, confirm that the description of your goals in your proxy statement will also be quantified. Kenneth B. Stratton StemCells, Inc. November 17, 2010 Page 2 You may contact Karen Ubell, Staff Attorn ey, at (202) 551-3873, Suzanne Hayes, Legal Branch Chief, at (202) 551-3675 or me at (202) 551-3715 with any questions. Sincerely, Jeffrey Riedler Assistant Director